Herceptin sBLA (correction)
Executive Summary
Roche/Genentech submitted a supplemental BLA for Herceptin for adjuvant treatment of early stage HER2-positive breast cancer in the first quarter and plan to file an sBLA for HER2-positive advanced gastric cancer in 2008; "The Pink Sheet" incorrectly reported that trastuzumabwas also under review for first-line, non-squamous non-small cell lung cancer (1"The Pink Sheet" June 26, 2006, p. 17). The firms' Avastin has an sBLA pending for that use...
You may also be interested in...
Roche To Build On Pharma, Diagnostics Expertise For Personalized Medicine
Roche sees its capabilities with both drug and diagnostics development as the key to maintaining a leadership position in targeted oncologics and personalized medicine
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.